Status
Acquired by Cubist Pharmaceuticals on July 30, 2013
Stock
TSRX
Founded:
2004
Headquarters:
Lexington, MA
Description:
Trius Therapeutics is focused on the development of innovative antibiotics for life-threatening infections.
Categories:
Health Care, Biotechnology
Website:
http://triusrx.com

Detailed Description

Update

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections.

We have successfully completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections.

Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory experience. Our senior management team consists of nine individuals who collectively have been involved in the development and approval of a significant number of anti-infective drugs.

Current Team (4)

Update

Past Team (1)

Update

Funding Rounds (2) - $49.3M

Update

Board Members and Advisors (2)

Update

Offices/Locations (1)

Update
  • Headquarters

    65 Hayden Avenue

    Lexington, MA 02421

    USA

Images (1)

Update
  • 09933ae296c398e2033f4a6102f4fbcc